ASA Wants Stock Perpetuals Paused. Retail Harm Is the Argument That Sticks.
The American Securities Association filed a November 10 brief backing interim relief in the fight over US single-stock perpetuals, arguing that retail investor damage during litigation can't be undone later. The CFTC's best defense is that these products beat offshore venues. That's a competition argument, not a safety one.
The American Securities Association wants a federal court to pause single-stock perpetuals, and it's leading with the argument that's hardest to wave off. Retail investors get hurt while everyone waits. The group's November 10 submission, made public on November 12, backs interim relief while the underlying challenge plays out.
Here's what matters: single-stock perps give traders outsized exposure to one name with borrowed capital and no expiry date. No settlement, no roll, no natural exit point. For an institutional desk, that's a tool. For a retail account running 20x on a momentum stock, it's a position that never asks you to make a decision until the liquidation engine makes it for you.
The legal hook is irreparable harm. And that's the right hook. Courts weighing interim relief ask whether damage done during litigation can be undone afterward. Money lost in a forced liquidation can't. A trader who gets flushed out overnight doesn't get made whole by a favorable ruling 14 months later. ASA is essentially telling the court that a win at trial is a loss in practice.
The CFTC has defended the products as a regulated domestic alternative to offshore trading. From a risk perspective, that's the strongest card the agency holds. Offshore perps already exist, they're two clicks away, and no US court order touches them.
But is onshore really the same as safer? Not automatically. Jurisdiction doesn't set margin caps. It doesn't change liquidation mechanics. It doesn't answer who's holding the bag when a thinly traded single-name book gaps through maintenance margin at 3am.
My read: the retail-harm framing is the most credible argument in this case, and it's the one the industry has the weakest answer to. The offshore comparison is real, but it's a competition argument. Courts weigh harm, not market share. That distinction is going to decide this one.
Watch the timing on relief. If the court pauses the products before the merits get argued, retail exposure outweighed product innovation in the judge's math. And if ASA's filing pulls state securities regulators into the fray, the CFTC ends up defending this thing on two fronts instead of one.
